Cost-effectiveness of balancing stroke and bleeding risk using CHA2DS2-VASc in primary care patients with Atrial Fibrillation: a management study. CAFe

Withdrawn

• Conditions: Atrial fibrillation; 10007963; stroke; 10007521

• Registration Number: NL-OMON37422
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 1250

Inclusion Criteria

Patients with known (paroxysmal or chronic) AF that are primarily treated by their general practitioner.

Exclusion Criteria

Being unable to give informed consent
Valvular disease or prosthetic valve

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Ischemic stroke or severe bleeding</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Health status as determined by SF-36 and EQ-5D questionnaires at baseline, 12<br /><br>months and 24 months follow-up </p><br>